Synergistic modulation of the gut microbiome-liver-host metabolome axis associates with the therapeutic efficacy of Danlou tablet against metabolic syndrome

BackgroundObesity drives chronic diseases such as cardiovascular disease and diabetes. Danlou tablet (DLT), a traditional Chinese medicine formula, is used to treat coronary heart disease by regulating lipid metabolism, suggesting potential for addressing obesity-related metabolic dysfunction. However, its role in obesity and insulin resistance remains unexplored.ObjectivesWe investigated the efficacy and mechanisms of DLT against high-fat diet (HFD)-induced obesity and insulin resistance.Method